Ca2+-mediated agonists, including
UTP, are being developed for
therapeutic use in
cystic fibrosis (CF) based on their ability to modulate alternative Cl- conductances. As CF is also characterized by hyperabsorption of Na+, we determined the effect of mucosal
UTP on transepithelial Na+ transport in primary cultures of human bronchial epithelia (HBE). In symmetrical NaCl,
UTP induced an initial increase in short-circuit current (Isc) followed by a sustained inhibition. To differentiate between effects on Na+ absorption and Cl- secretion, Isc was measured in the absence of mucosal and serosal Cl- (INa). Again, mucosal
UTP induced an initial increase and then a sustained decrease that reduced
amiloride-sensitive INa by 73%. The Ca2+-dependent
agonists histamine,
bradykinin, serosal
UTP, and
thapsigargin similarly induced sustained inhibition (62-84%) of INa. Mucosal
UTP induced similar sustained inhibition (half-maximal inhibitory concentration 296 nM) of INa in primary cultures of human CF airway homozygous for the DeltaF508 mutation.
BAPTA-AM blunted
UTP-dependent inhibition of INa, but inhibitors of
protein kinase C (PKC) and
phospholipase A2 had no effect. Indeed, direct activation of PKC by
phorbol 12-myristate 13-acetate failed to inhibit Na+ absorption.
Apyrase, a tri- and diphosphatase, did not reverse inhibitory effects of
UTP on INa, suggesting a long-term inhibitory effect of
UTP that is independent of receptor occupancy. After establishment of a mucosa-to-serosa K+ concentration gradient and permeabilization of the mucosal membrane with
nystatin, mucosal
UTP induced an initial increase in K+ current followed by a sustained inhibition. We conclude that increasing cellular Ca2+ induces a long-term inhibition of transepithelial Na+ transport across normal and CF HBE at least partly due to downregulation of a basolateral membrane K+ conductance. Thus
UTP may have a dual
therapeutic effect in CF airway: 1) stimulation of a Cl- secretory response and 2) inhibition of Na+ transport.